- Home
- DSGR vs OCS Comparison
DSGR vs OCS Comparison
Compare DSGR & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSGR | OCS |
|---|---|---|
| Founded | 1952 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | DSGR | OCS |
|---|---|---|
| Price | $22.12 | $26.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $41.00 | ★ $41.86 |
| AVG Volume (30 Days) | 89.0K | ★ 308.0K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 212.50 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $1,980,023,000.00 | N/A |
| Revenue This Year | $7.12 | $418.43 |
| Revenue Next Year | $4.24 | $892.34 |
| P/E Ratio | $121.39 | ★ N/A |
| Revenue Growth | ★ 9.75 | N/A |
| 52 Week Low | $21.27 | $14.00 |
| 52 Week High | $33.80 | $30.68 |
Technical Indicators
Market Signals| Indicator | DSGR | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 16.59 | 43.56 |
| Support Level | N/A | $25.99 |
| Resistance Level | $28.80 | $29.23 |
| Average True Range (ATR) | 1.16 | 1.04 |
| MACD | -0.89 | -0.44 |
| Stochastic Oscillator | 8.50 | 2.58 |
Price Performance
Historical ComparisonAbout DSGR Distribution Solutions Group Inc.
Distribution Solutions Group Inc is an industrial distributor of maintenance and repair supplies. It has three operating segments namely Lawson, TestEquity, and Gexpro Services, of which key revenue is derived from the TestEquity segment. The TestEquity segment is a distributor of test and measurement equipment and solutions, electronic production supplies, and tool kits from its manufacturer partners supporting the technology, aerospace, defense, automotive, electronics, education and medical industries.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.